Corruption Probe Could Be A Double-Edged Sword For Chinese Domestic Makers
This article was originally published in PharmAsia News
Chinese domestic pharmaceutical executives have been mostly tight-lipped about the government’s ongoing anti-corruption investigation, which has mainly targeted multinationals. But recent developments indicate that local companies may soon feel the heat.
You may also be interested in...
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
A former pharma executive shares views with Scrip about the coronavirus in China, the challenges facing corporations and individuals in a rapidly changing world and coming threats that could potentially cause even more damage than the pandemic.
Leveraging its Ebola vaccine success, Tianjin-based CanSino is looking to launch China’s first vaccine for COVID-19 as it secures permission to start local clinical trials.